Selecting Good 'Drug-Like' Properties to Optimize Small Molecule Blood-Brain Barrier Penetration

被引:28
作者
Trippier, Paul C. [1 ,2 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 1300 S Coulter, Amarillo, TX 79106 USA
[2] Texas Tech Univ, Dept Chem & Biochem, Ctr Chem Biol, Lubbock, TX 79409 USA
关键词
Blood-brain barrier; Drug-likeness; Central Nervous System; Neuropharmacology; Physicochemical Properties; Drug Design; CENTRAL-NERVOUS-SYSTEM; IN-SILICO PREDICTION; PLASMA-CONCENTRATION RATIO; P-GLYCOPROTEIN; ENDOTHELIAL-CELLS; ADME EVALUATION; UNBOUND BRAIN; VITRO MODELS; PASSIVE PERMEABILITY; SLICE METHOD;
D O I
10.2174/0929867323666160405112353
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The success rate to achieve clinical approval of drugs developed to treat diseases of the central nervous system (CNS) is the lowest of all disease indications. A large contributor to this poor success rate is failure of small molecules to pass through the blood-brain barrier (BBB), a barrier composed of capillary endothelial cells connected by tight junctions that functions to extrude xenobiotics from the brain. Designing small molecules to be BBB penetrant has been the subject of intensive research and has resulted in a series of guidelines to attain the best possible chances of BBB penetration. This review will analyze the current state of thinking in ranking the importance of various physicochemical properties required to select BBB penetrant molecules, describe model systems to determine BBB penetration, summarize data analysis methods and provide an outlook on further developments in the field.
引用
收藏
页码:1392 / 1407
页数:16
相关论文
共 141 条
  • [11] The blood-brain barrier: an overview - Structure, regulation, and clinical implications
    Ballabh, P
    Braun, A
    Nedergaard, M
    [J]. NEUROBIOLOGY OF DISEASE, 2004, 16 (01) : 1 - 13
  • [12] Bickel Ulrich, 2005, NeuroRx, V2, P15, DOI 10.1007/BF03206639
  • [13] Boje K. M., 2001, CURR PROTOC NEUROSCI
  • [14] Improving the prediction of the brain disposition for orally administered drugs using BDDCS
    Broccatelli, Fabio
    Larregieu, Caroline A.
    Cruciani, Gabriele
    Oprea, Tudor I.
    Benet, Leslie Z.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 (01) : 95 - 109
  • [15] BDDCS Class Prediction for New Molecular Entities
    Broccatelli, Fabio
    Cruciani, Gabriele
    Benet, Leslie Z.
    Oprea, Tudor I.
    [J]. MOLECULAR PHARMACEUTICS, 2012, 9 (03) : 570 - 580
  • [16] Brooks David J, 2005, NeuroRx, V2, P226
  • [17] Blood-brain barrier permeability mechanisms in view of quantitative structure-activity relationships (QSAR)
    Bujak, Renata
    Struck-Lewicka, Wiktoria
    Kaliszan, Michal
    Kaliszan, Roman
    Markuszewski, Michal J.
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2015, 108 : 29 - 37
  • [18] ELECTRICAL-RESISTANCE ACROSS THE BLOOD-BRAIN-BARRIER IN ANESTHETIZED RATS - A DEVELOPMENTAL-STUDY
    BUTT, AM
    JONES, HC
    ABBOTT, NJ
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 1990, 429 : 47 - 62
  • [19] Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight
    Camenisch, G
    Alsenz, J
    van de Waterbeemd, H
    Folkers, G
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 6 (04) : 313 - 319
  • [20] In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms
    Chen, Hongming
    Winiwarter, Susanne
    Friden, Markus
    Antonsson, Madeleine
    Engkvist, Ola
    [J]. JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2011, 29 (08) : 985 - 995